Citations

Clear

6273 citation(s) found for "To, Andrew".

Modifiable risk-factors, genetic characteristics, and survival in early-onset cholangiocarcinoma.
O’Donnell, Conor, Shah, Priyanshi , Ness, Andrew, Pirozzi, Angelo , Okano, Naohiro, Kamatham, Saivaishnavi , Nunnelee, Jordan , Ness, Andrew, Majeed, Umair , Babiker, Hani M. , Borad, Mitesh J. , Okano, Naohiro , Mosalem, Osama , Ou, Fang‐Shu , Tran, Nguyen H.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 4085-4085

10.1200/jco.2025.43.16_suppl.4085 Get It

4085 Background: Cholangiocarcinoma (CC) is a rare disease with an increasing incidence among younger adults, which is poorly understood. Genomic profiling of tumors is both prognostic and predictive of benefit for targeted therapies. We investigated if there are clinical and molecular differences between younger vs older patients with CC. Methods: We collected TEMPUS genetic data via retrospective chart review from tumors in young vs old patients seen at our institution, defined as ≤50 vs > 50 years of age at time of diagnosis. We included patients diagnosed with CC between January 2008 and July 2024 with available clinical follow up and TEMPUS genetic sequencing data. We collected mutation data on the following actionable genes: FGFR2, IDH1/2, BRCA1, BRCA2, BRAF, ATM, ERBB2/3, and KRAS. Patient characteristics and gene expression variables were compared using Chi-square, Fisher’s exact and Wilcoxon rank-sum tests. Kaplan-Meier, log rank tests and a multivariable Cox model were used for survival analysis. This study was IRB exempt. Results: We included 410 patients, 84 in the young group with median age at diagnosis of 40.8 years, and 326 in the old group with median age 68.5 years. 91.5% of patients were white. There was no difference in BMI between groups, however the older group had higher rates of hypertension (15.5% vs 57.7%), hyperlipidemia (6.0% vs 49.7%), cardiovascular disease (1.2% vs 20.6%), and type 2 diabetes (6.0% vs 21.5%), (all p < 0.01). Primary sclerosing cholangitis was more common in the young group (26.2% vs 4.3%, p < 0.01). ECOG status of 0 at first treatment was seen in 65.3% of young vs 52.5% of old patients (p = 0.02). FGFR2 alterations were more common in the young group (17.9% vs 8.0%, p < 0.01), while ATM mutations were more common in old vs young (5.5% vs 0%, p = 0.03). There was no age difference seen for the other genetic alterations. Mean tumor mutational burden was higher in the old group (4.1 vs 3.8 mut/mb, p = 0.01). MSI-high was found in 2% of cases with no difference between groups. There was no significant difference in overall survival between age groups. There was a numeric difference in overall survival in stage IV patients, though not statistically significant (17.8 months vs. 16.3 months, p = 0.08). In a multivariable Cox analysis, female sex, earlier stage at diagnosis and clinical trial enrollment were associated with favorable prognostics. Conclusions: Our data highlight relatively low rates of comorbidities associated with metabolic dysfunction in younger adults with CC, suggesting alternative factors are likely to explain the increasing incidence of early-onset disease. FGRFR2 is a more common pathogenic alteration among the young and could inform targeted therapies. Younger patients with CC may not have improved survival outcomes compared to their older counterparts. This underscores the aggressive nature of CC and the need for more effective therapies to improve outcomes.
Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Application toward p
Weiskittel, Taylor M. , Koukol, Austin , Kellinger, Caroline, Seifarth, Christopher, Zhang, Leiqing , Carneiro, Benedito A. , El‐Deiry, Wafik S. , Mazar, Andrew P. , Ugolkov, Andrey , Seifarth, Christopher, Li, Hu , Mahalingam, Devalingam

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 4185-4185

10.1200/jco.2025.43.16_suppl.4185 Get It

4185 Background: Elraglusib is a first-in-class inhibitor of GSK-3ß, a well-credentialed target in cancer implicated in intrinsic oncologic processes and tumor immune response. Preliminary results of the 1801 Part 3B trial (NCT03678883) showed statistically significant benefits for elraglusib+GnP versus GnP for 1-year survival and mOS in mPDAC (companion abstract: Mahalingam et al.). We investigated plasma levels of cytokines/chemokines/soluble cell receptors/growth factors (CCSG) as potential biomarkers of favorable outcomes on elraglusib. Methods: Forty CCSGs were evaluated in pre-dose plasma from patients with previously untreated mPDAC enrolled in 1801 Part 3B treated with GnP (n = 78) or elraglusib+GnP (n = 155) using a Luminex immunoassay. Using Kaplan-Meier statistics and cutpoint determination, CCSGs were assessed for OS predictive ability in the elraglusib+GnP arm. Multivariate models were constructed to predict binarized survival at 12 months using machine learning (ML). Fivefold cross-validation was used in both analyses, and all methods were applied to the GnP arm to identify elraglusib+GnP specific predictors. Results: Data shown as of November 15, 2024. Multiple CCSGs significantly stratified elraglusib+GnP patients. The most extreme prognosticators were IFN-ß (average HR = 2.34), and PD-L1 (average HR = 0.52) (HR shown as high CCSG vs low CCSG). Screening of different ML approaches ranked logistic regression at the top, and hyperparameter grid search identified stochastic gradient solver with ridge regularization as the optimal method. The model had an accuracy of 88% (SD: 3.9%) and a balanced accuracy of 80% (SD: 8.5%). IFN-beta had the most substantial effect size (odds ratio (OR) = 72.28), followed by IL-18 (OR = 23.38) and PD-L1 (OR = 15.32). All other CCSGs had an OR between 0.03 and 6.71. When this model was applied to patients in the GnP arm, accuracy was 68.4%, and balanced accuracy was 43.1%. Conclusions: Many CCSG biomarkers were identified as promising predictors of survival benefit in mPDAC patients treated with elraglusib+GnP. Both univariate statistical and multivariate ML approaches show predictive significance with high interpretability. The initial ML model is specific to elraglusib treatment, not GnP alone. These results indicate that patients’ initial immune state plays a role in response to elraglusib+GnP. However, single CCSGs for enrichment currently exclude too many patients ( > 75%), and thus, panels of biomarkers are being investigated with ML to overcome this limitation. The 1801 Part 3B clinical trial recruitment has been completed, and updated biomarker models reflective of topline OS data, available by April 2025, will be presented.
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Shroff, Rachna T. , Carneiro, Benedito A. , Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Percent, Ivor , Pernot, Simon , Kavan, Petr , Mulcahy, Mary F. , Mazar, Andrew P. , Fine, Gil D., Sahai, Vaibhav , Mahalingam, Devalingam , Ji, Yan , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Lopez, Charles D. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 4006-4006

10.1200/jco.2025.43.16_suppl.4006 Get It

4006 Background: Elraglusib (9-ING-41) is a first-in-class inhibitor of GSK-3ß, which may mediate drug resistance, EMT, and damaged DNA and tumor immune response in advanced cancer. In pancreatic cancer models in mice, elraglusib combined with chemotherapy enhanced anti-tumor effects and survival. In a single-arm clinical study, elraglusib/GnP showed antitumor activity and prolonged survival in pts with mPDAC. Methods: Pts with previously untreated mPDAC were randomized 2:1 to GnP plus elraglusib 9.3 mg/kg IV once weekly or GnP in an open-label phase 2 study. The primary endpoint was 1-yr OS in the primary analysis set. Upon study completion, mOS will be the primary endpoint once survival distributions are compared after the 12-month follow-up using log-rank analysis. Secondary endpoints included DCR, ORR, mPFS, and TEAEs/TRAEs. The planned sample size was 207 evaluable pts (130 for elraglusib/GnP and 77 for GnP), assuming 1-yr OS of 55% with elraglusib/GnP and 35% with GnP to achieve 80% power with a chi-square test at a 2-sided 5% α. For OS, nonparametric log-rank test was used with statistical significance at p-value < 0.048. Cytokine/chemokine correlative biomarker assays were performed. The study completed enrollment in February 2024. Results: As of November 15, 2024 (preliminary data cut-off date), the primary analysis set included 155 pts in the elraglusib/GnP arm and 78 pts in the GnP arm, with 52.8% males and 57.5% ECOG PS 1. Median (range) CA 19-9 levels were 1568 U/mL (1 to 381,904 U/mL) in the elraglusib/GnP arm and 1590 U/mL (2 to 501,000 IU/mL) in the GnP arm. The 1-yr OS rate was 43.6% with elraglusib/GnP vs 22.5% with GnP (z-test p = 0.002); the mOS was 9.3 mo with elraglusib/GnP vs 7.2 mo with GnP (HR, 0.63; log rank p = 0.016; see Table). 38.1% of pts on elraglusib/GnP and 19.2% on GnP are censored, with the majority at > 10 months OS. Several biomarkers appear to be predictive for OS including IFNβ and PD-L1. The most common TRAE with elraglusib/GnP was grade 1-2 transient visual impairment in > 60% of patients (vs 9% with GnP). Grade ≥3 TEAEs occurred in 89.7% of pts on elraglusib/GnP and 80.8% on GnP. Most common grade ≥3 TEAEs with elraglusib/GnP (vs GnP) were neutropenia 51.6% (vs 29.5%), anemia 24.5% (vs 29.5%), and fatigue 16.1% (vs 5.1%). Conclusions: The preliminary results showed a statistically significant benefit for 1-yr OS and mOS and favorable trends for ORR and DCR with elraglusib/GnP over GnP, with manageable safety profile. The mOS for GnP is lower relative to MPACT and NAPOLI-3 but comparable to recent real-world meta-analyses, explained by advanced disease burden and higher mortality rate in the first 4 months in our study. Topline analysis (April 2025) and correlative biomarker analysis predictive for OS will be presented. Clinical trial information: NCT03678883 . Preliminary efficacy results. Elraglusib/GnPn=155 GnPn=78 1-year OS, %z-test p=0.002 43.6 22.5 mOS, moHR=0.63; log-rank p=0.016 9.3 7.2 Events, n (%) 96 (61.9) 63 (80.8) mPFS, moHR=0.91; p=NS 5.6 4.9 Events, n (%) 128 (82.6) 70 (89.7) DCR, % 42.6 33.3 ORR, n (%) 43 (27.7) 16 (20.5)
Evaluating the utility of DNA methylation signatures in tissue and biofluids for lung adenocarcinoma brain metastasis prediction and non-invasive detection.
Zuccato, Jeffrey , Nassiri, Farshad , Ajisebutu, Andrew, Suppiah, Suganth , Saarela, Olli , Aldape, Kenneth , Zadeh, Gelareh, Mamatjan, Yasin , Liu, Jeff , Voisin, Mathew , Tsao, Ming‐Sound , Patil, Vikas S.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 2030-2030

10.1200/jco.2025.43.16_suppl.2030 Get It

2030 Background: Brain metastases (BM) are common and arise in 30% of lung adenocarcinoma (LUAD) patients. Patients with LUAD that develop BM have significantly poorer outcomes, with a 10-16 month median overall survival. Unfortunately, current clinical practice for BM prediction is limited and so BM are typically detected after they develop and grow to cause neurological symptoms. Once BM are detected, currently neurosurgical tumor biopsies are performed to enable BM diagnosis via neuropathological evaluation. The aims of this study were to develop DNA methylation-based models that predict LUAD BM and non-invasively detect BM in blood to enable early diagnosis and treatment. Methods: DNA methylomes were acquired from 402 tumor tissue and plasma samples in a cohort of 346 LUAD and BM patients. Machine learning models were built using DNA methylation signatures that stratify BM risk in tissue and detect BM in plasma. Models were evaluated in independent validation datasets. A predictive nomogram was developed using the BM prediction model together with clinical factors to provide composite patient-specific scores reflecting BM risk. Results: The methylation-based BM predictor accurately stratified BM risk in a univariable Cox model using validation set data (HR = 5.65, 95%CI 1.85–17.2, p = 0.0023). Model utility was independent of the predictive value of clinical factors in a multivariable Cox model using validation set data (Table 1: HR = 8.92, 95%CI 1.97–40.5, p = 0.0046). The 5-year model accuracy was 0.81 and significantly higher than a similarly built cancer stage-based model (0.65), demonstrating utility over current practice. The combinatorial clinical-methylomic predictive nomogram had enhanced utility with an accuracy of 0.82 univariable Cox HR of 17.2 (95%CI 4.13–71.3, p < 0.0001), demonstrating comprehensive patient-specificity. The plasma-based model accurately classified BM from gliomas and lymphomas (AUROC=0.80), as typical clinical differential diagnoses, in validation set data. The models were validated further in additional external data. Conclusions: DNA methylation-based modeling of BM can accurately predict LUAD patients at risk for BM development and can non-invasively detect BM that develop. Future treatment approaches may tailor initial LUAD treatment and ongoing cancer surveillance to a patient’s BM risk, allowing for the potential to prevent and treat BM early. DNA methylation-based BM prediction is independent of clinical factors in a multivariable Cox proportional hazards model. Variable HR 95% CI p Methylome risk score 8.92 1.97–40.5 0.005 Age Years 0.96 0.92–1.02 0.177 Smoking Pack-years 0.99 0.95–1.03 0.496 EGFR Mutant vs wildtype 0.92 0.25–3.34 0.895 T T2 vs T1 1.58 0.41–6.04 0.505 T3−4 vs T1 1.49 0.28–7.98 0.642 N N1 vs N0 1.05 0.31–3.58 0.943 N2−3 vs N0 1.00 0.27–3.69 0.995 M M1 vs M0 145 12.2–1730 <0.001
Real-world analysis of 2IR immune response score in histologic subtype urothelial carcinoma (hsUC).
Bilen, Mehmet Asım , Stewart, Tyler F. , McKay, Rana R. , Heath, Elisabeth I. , Geynisman, Daniel M., Smith, Norm, Brown, Jason R. , Adeyelu, Tolulope Tosin , Elliott, Andrew , Basu, Arnab , Li, Roger , Geynisman, Daniel M. , Barata, Pedro C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 4568-4568

10.1200/jco.2025.43.16_suppl.4568 Get It

4568 Background: The 2IR immune response score was initially developed using bulk RNA sequencing of pre-treatment tissue from ImVigor 210 and CheckMate 275 trials, however these trials enrolled patients (pts) with pure urothelial carcinoma (pUC) histology. Patients with hsUC often exhibit worse response to immune checkpoint inibitors (ICI) than patients with pUC. Here, we evaluated the 2IR score as a prognostic or predictive biomarker in real-world pts with hsUC. Methods: Specimens from pts with pUC (n = 1677) and hsUC (n = 417) were profiled at Caris Life Sciences (Phoenix, AZ) using next generation sequencing (NGS) of DNA and RNA. HsUC histologies included majority ( > 50%) squamous (n = 340), sarcomatoid (n = 51), neuroendocrine (n = 20), and micropapillary (n = 6) component. 2IR was calculated by comparative RNA expression of 10 adaptive immune genes and 39 pro-tumorigenic genes. Tumors were classified as 2IR-Low (2IR ≤ -0.5), -Mid (-0.5 < 2IR < 0), and -High (2IR ≥ 0), as previously described (Wang et al., 2022). Spearman correlation analysis was utilized to compare 2IR with tumor mutation burden (TMB), interferon score (IFN) and the tumor microenvironment (TME) cell fractions estimated using quanTIseq. Clinical outcomes included real-world overall survival (rwOS) from ICI start to last contact and time on treatment (ToT) with pembrolizumab, obtained via matched insurance claims data and calculated using Kaplan-Meier methods, while Hazard ratio (HR) was calculated by Cox proportional model. Results: For patients with hsUC, distribution of 2IR score was High 5.76%, Mid 33.3%, and Low 60.9%. Median 2IR score was significantly lower in squamous (-0.60, p < 0.0001) and sarcomatoid UC (-0.82, p < 0.0001) compared to pUC (-0.41) and significantly higher in neuroendocrine UC (-0.15, p = 0.003). Among patients with hsUC, median rwOS was significantly longer for patients with high/mid 2IR score compared to low 2IR score (25.3 [10.9-39.3] months vs. 8.7 [6.2-11.3] months; HR 0.52, 95% CI 0.34 – 0.78, p = 0.0017). ToT with pembrolizumab was also significantly longer for high/mid 2IR score compared to low 2IR score (3.0 [1.4-5.5] months vs. 2.1 [1.4-3.3] months; HR 0.68, 95% CI 0.46-1.00, p = 0.0471). Similar to pUC, 2IR score in patients with squamous UC was positively associated with CD8 T cell infiltration (r = 0.39; p < 0.0001), IFN score (r = 0.41, p < 0.0001), and TMB (r = 0.20, p < 0.001) and negatively associated with M1 macrophage infiltration (r = -0.25, p < 0.0001). 2IR scores in hsUC correlated positively but not significantly with mutations in TP53 (Median: -0.59 vs -0.62, p = 0.067) and PIK3CA (Median: -0.56 vs -0.61, p = 0.172) and negatively with mutations in CDKN2A (Median: -0.67 vs -0.59, p = 0.052). Conclusions: In a real-world cohort of patients with hsUC, we show the 2IR score may be prognostic for rwOS and predictive for pembrolizumab ToT. Prospective studies are needed to further validate this biomarker for use in this population.
Call for a Translational Orthobiologics Fellowship in the Era of Regenerative Medicine
Strader, Shannon , Villasenor, Andrew, Wyles, Saranya P. , Chandan, Priya , Terzic, Carmen M., Bean, Allison , Wyles, Saranya, Terzic, Carmen, Strader, Shannon R , Master, Zubin

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | May 28, 2025 | Volume: 104 | Issue: 9 | Pages: 831-837

10.1097/phm.0000000000002782 | PMID 40434440 Get It

Abstract Regenerative medicine is a rapidly advancing field, particularly within the field of physical medicine and rehabilitation. While orthobiologics are currently being used in clinical practice, there remains a need for high-quality clinical trials and translational research to standardize treatments and improve patient outcomes. Education is vital for streamlining development of evidence-based, practical, and effective treatments. In this article, we highlight the need for a 1-yr advanced fellowship in translational orthobiologics aiming to create a standardized core curriculum targeting physicians involved in treating musculoskeletal diseases. The fellowship’s objectives include advancing translational orthobiologics research, ethical considerations, and promoting effective communication regarding orthobiologic therapies. Such a program would serve as a foundation for physicians interested in conducting clinically oriented orthobiologics research for musculoskeletal disorders while improving the development of safe and effective therapeutics related to musculoskeletal disorders.
A new estimation equation to assess body composition in an athletic population
Magee, Meghan K., Miller, Angela D. , Stroiney, Debra A., Lockard, B , Jones, Margaret T. , Jagim, Andrew R , Jones, Margaret T , Jagim, Andrew R.

Mayo Clinic

Journal of the International Society of Sports Nutrition | May 28, 2025 | Volume: 22 | Issue: 1 | Pages: No page available

10.1080/15502783.2025.2504578 | PMID 40434031 Get It

A comparative study on the effect of age on Neck Disability Index improvement at 24 months after surgical intervention for cervical spondylotic myelopathy: a Quality Outcomes Database study
Sherrod, Brandon A. , Rosero, Spencer , Chan, Andrew K. , Shaffrey, Christopher I., Gottfried, Oren N., Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Tumialán, Luis M. , Turner, Jay D. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Bisson, Erica F. , Porche, Ken M. , Shaffrey, Christopher I. , Fu, Kai-Ming, Uribe, Juan S. , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | May 23, 2025 | Volume: 43 | Issue: 2 | Pages: 154-169

10.3171/2025.3.spine24598 | PMID 40408883 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) is often accompanied by neck pain, which, along with more recognized neurological deficits like motor and sensory changes, significantly impacts patients’ quality of life. The authors examined whether age influences improvements in neck disability and related quality-of-life measures after surgery for CSM. Using the Neck Disability Index (NDI) as the primary outcome, they compared long-term outcomes at 24 months among patients aged ≥ 65, ≥75, and < 65 years, exploring the effects of surgical intervention on both pain-related disability and functional recovery in older adults. METHODS Using the Quality Outcomes Database, the authors conducted a detailed propensity score–matched analysis on cohorts aged ≥ 65 and ≥ 75 years compared with a < 65-year-old cohort while controlling for baseline NDI scores, other demographic variables, health status, underlying pathology, number of levels, indication for surgery, surgical approach, and type of surgery. Differences in NDI total and subdomain scores at 24 months postoperatively were the primary measures of improvement. Age-related variability in NDI differential was assessed. EQ-5D and calculated SF-6D were secondary measures. RESULTS Of the 1141 patients in the cohort (January 2016 to December 2018), 687 patients were < 65 years, 325 were 65 to < 75 years, and 129 were ≥ 75 years of age. After propensity score matching, 197 patients each were well matched in the ≥ 65-year (mean 71.4 years) and < 65-year (mean 55.3 years) cohorts; similarly, 57 patients each were matched in the ≥ 75-year (mean 78.3 years) and < 65-year (mean 55.8 years) cohorts. Improvements in NDI scores and subdomain scores, EQ-5D, and calculated SF-6D were consistent at 3, 12, and 24 months postoperatively across all cohorts. At 24 months, patients ≥ 65 years showed NDI score improvements (−14.7 ± 22.3) similar to those < 65 years (−13.0 ± 21.3, p = 0.454), and patients ≥ 75 years demonstrated NDI improvements (−15.0 ± 19.7) comparable to those < 65 years (−17.6 ± 20.4, p = 0.499). A sensitivity analysis for linear relationship found that NDI improvement was statistically greater in older patients (7.5 points every 30 years, p < 0.0001), but this difference was below the minimal clinically important difference. Other clinical outcomes were similar between cohorts. CONCLUSIONS Surgical intervention for CSM yields substantial and similar improvements in NDI scores and other metrics among various age groups, including those aged at least 65 and 75 years. These results highlight the effectiveness of surgery across a broad patient demographic, underscoring its value in treating CSM irrespective of age.
Context-dependent trade-offs in body size among Olympic sports
Kipp, Shalaya , Husen, Martin , Wiggins, Chad C. , Gorman, Ellen K. , Clayburn, Andrew J. , Joyner, Michael J. , Senefeld, Jonathon W. , Wiggins, Chad C , Joyner, Michael J , Senefeld, Jonathon W , Kipp, Shalaya

Mayo Clinic

Applied Physiology, Nutrition, and Metabolism | May 23, 2025 | Volume: 50 | Issue: No issue available | Pages: 1-8

10.1139/apnm-2025-0021 | PMID 40408782 Get It

There is a context-dependent trade-off in body size of elite runners, such that smaller body sizes are observed among longer distance runners. However, it is unclear whether this trade-off in body size is observed in other Olympic sports, such as cycling and swimming. To understand the association between body size and athletic competition, we examined metrics of body size from male and female Olympic athletes competing in swimming, running, and cycling. We collected standard anthropometrics (height, mass, body mass index (BMI), and body surface area) of elite male and female athletes competing in the London 2012 Summer Olympics from a public repository. Anthropometric data were compared between sexes (male and female); between sports (swimming, running, and cycling); and between distances within sports (shorter and longer distance). Males were taller ( P < 0.001), heavier ( P < 0.001), and had a larger BMI ( P < 0.001) compared to females. Relative to athletes competing in longer distance events, athletes competing in shorter distance were generally taller (running: P < 0.001, swimming: P ≤ 0.014) and heavier (running: P < 0.001, swimming: P = 0.002 (males) and P = 0.148 (females), cycling: P < 0.001) for both males and females. Height was not different between shorter and longer distance cyclists. There was a trade-off between body size and distance for each of the three Olympics sports, such that smaller athletes were observed in longer distance events. Although there were large sex-based differences in body size, similar trade-offs in size and event were observed for both males and females. These data suggest that there is an optimal combination of skeletal muscle mass and body size to optimize movement economy that is generally preserved across different modes of human locomotion.
Outcomes of medical and surgical management in infectious intracranial aneurysms: a multicenter cohort analysis
Alawieh, Ali , Zohdy, Youssef M. , Koo, Andrew B. , Saad, Hassan , Baba, Bachar El , Newman, Sarah, Grossberg, Jonathan A , Matouk, Charles , Cawley, C. Michael, Reisner, Andrew , Perez‐Vega, Carlos , Burkhardt, Jan‐Karl , Salem, Mohamed M , Jabbour, Pascal , Naamani, Kareem El, Gooch, M Reid, Starke, Robert M., Abdelsalam, Ahmed , Lu, Victor M , Chalhoub, Reda , Spiotta, Alejandro M , Alawieh, Ali M , Zohdy, Youssef M , Koo, Andrew B , El Baba, Bachar , Grossberg, Jonathan A , Matouk, Charles , Fox, W Christopher , Perez-Vega, Carlos , Jabbour, Pascal , Levitt, Michael R , Chalhoub, Reda M , Spiotta, Alejandro M , Howard, Brian M , Burkhardt, Jan‐Karl , Dimisko, Laurie , Pradilla, Gustavo , Naamani, Kareem El , Schmidt, Richard F. , Gooch, Michael Reid , Abdelsalam, Ahmed, Levitt, Michael R. , Kobeissy, Firas , Barrow, Daniel L.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 23, 2025 | Volume: 18 | Issue: 4 | Pages: 1079-1086

10.1136/jnis-2025-023421 | PMID 40409986 Get It

Introduction Infectious intracranial aneurysms (IIAs) are rare but serious complications of systemic infections, particularly infective endocarditis. These aneurysms are prone to rupture, leading to significant morbidity and mortality. Management strategies lack consensus due to the rarity of the condition and reliance on small case series. This study examines the clinical management of IIAs using data from a large multicenter cohort. Methods A retrospective registry-based cohort study was conducted across 11 tertiary care centers in the USA between 2018 and 2023. Patients with IIAs were identified based on clinical and radiographic criteria. The primary outcome was treatment failure defined as persistence, growth, or rupture of the aneurysm. Secondary outcomes were mortality and the modified Rankin Scale (mRS) score at 90 days and 1 year. Multivariate logistic regressions were used to identify outcome predictors. Results A total of 104 patients with 166 aneurysms were included, with a median age of 43 years. Medical management was successful in 56% of cases, with failure often within 18 days of initiation. Predictors of failure included younger age, larger aneurysm size, and rupture at presentation. Surgical and endovascular interventions achieved higher success rates with better outcomes. At 90 days, 57% of patients achieved functional independence (mRS 0–2), while the mortality rate was 24%. Conclusion This study highlights the limitations of medical management for IIAs and underscores the need for early surgical or endovascular intervention in high-risk patients. Outcome predictors aid clinical decision-making, optimizing patient management. Further research is needed to standardize management guidelines for IIAs.